{
    "clinical_study": {
        "@rank": "117568", 
        "acronym": "SCART", 
        "arm_group": {
            "arm_group_label": "Selumetinib treatment", 
            "arm_group_type": "Experimental", 
            "description": "Dose-finding study of selumetinib in combination with HAART (phase I) and efficacy at recommended phase 2 dose."
        }, 
        "brief_summary": {
            "textblock": "Cancer is a leading cause of death in individuals living with HIV, and Kaposi's sarcoma (KS)\n      remains the commonest HIV-associated cancer. KS results from co-infection with HIV and\n      another virus, HHV-8. Laboratory studies have shown that HHV-8 viral proteins stimulate\n      intracellular signalling pathways within KS lesions which promotes their growth. Selumetinib\n      targets these signalling pathways and may therefore be a useful new therapy for KS."
        }, 
        "brief_title": "A Study of Selumetinib in Patients With Kaposi's Sarcoma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "AIDS-related Kaposi's Sarcoma", 
        "condition_browse": {
            "mesh_term": [
                "Acquired Immunodeficiency Syndrome", 
                "Sarcoma, Kaposi", 
                "AIDS-Related Opportunistic Infections", 
                "Sarcoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed KS.\n\n          -  Measurable disease according to ACTG criteria.\n\n          -  Evidence of disease progression in the past 6 months, without anticancer treatment\n             since progression.\n\n          -  Progressive cutaneous or nodal KS not requiring chemotherapy OR progressive KS\n             following cytotoxic chemotherapy.\n\n          -  Adequate haematological function:\n\n               -  Haemoglobin \u2265 9 g/dL\n\n               -  Absolute neutrophil count \u2265 1.5 x 10 9/L\n\n               -  Platelets \u2265 100 x 10 9/L\n\n          -  Adequate hepatic function:\n\n               -  Serum bilirubin \u2264 1.5 x upper limit of normal (ULN)\n\n               -  ALT \u2264 2.5 x ULN\n\n               -  AST \u2264 2.5 x ULN\n\n          -  Adequate renal function:\n\n               -  Serum creatinine clearance > 50 ml/min (Cockcroft-Gault formula or 24 hour urine\n                  collection).\n\n          -  Left ventricular function >50% normal\n\n          -  Age \u2265 18 years.\n\n          -  ECOG performance status \u2264 2.\n\n          -  For selumetinib, women of child bearing age and child bearing potential MUST have a\n             negative pregnancy test prior to study entry AND be using an adequate contraception\n             method, which must be continued while on treatment and for at least 4 weeks after the\n             study treatment has ended.\n\n          -  Male patients must agree to use an effective contraception method while on treatment\n             and for at least 16 weeks after the study treatment has ended (barrier contraception\n             is recommended for all individuals living with HIV).\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  HIV viral load > 200 copies/ml.\n\n          -  Any previous treatment with a Ras, Raf or MEK inhibitor.\n\n          -  Active opportunistic infections.\n\n          -  Known hepatitis B, hepatitis C.\n\n          -  Clinical evidence of uncontrolled hypertension (systolic BP > 150 mmHg or diastolic\n             BP > 90 mmHg on 2 readings \u2265 1 hour apart).\n\n          -  Clinical evidence of heart failure (\u2265NYHA Class II).\n\n          -  Clinical evidence of atrial fibrillation (heart rate > 100 bpm) or unstable ischaemic\n             heart disease (MI within 6 months prior to starting treatment or angina requiring the\n             use of nitrates > once weekly).\n\n          -  Major surgery within 4 weeks prior to starting selumetinib.\n\n          -  Evidence of any psychological, familial, sociological or geographical condition\n             potentially hampering protocol compliance.\n\n          -  Clinical judgement by the Investigator that the patient should not participate in the\n             study.\n\n          -  Refractory nausea, vomiting, chronic gastrointestinal diseases (e.g. inflammatory\n             bowel disease) or significant bowel resection that would preclude adequate\n             absorption.\n\n          -  Treatment with any investigational product within 28 days of registration\n\n          -  Pregnant or breast-feeding women."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01752569", 
            "org_study_id": "STH16059", 
            "secondary_id": "2011-003099-35"
        }, 
        "intervention": {
            "arm_group_label": "Selumetinib treatment", 
            "description": "Dose schedule:\n-1 75 mg od (75 total) --\n(starting) 50 mg bd (100 total)\n75 mg bd (150 total)\n100 mg bd (200 total) Selumetinib should be taken twice daily approximately 12 hours apart with water (for BD doses), at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.", 
            "intervention_name": "Selumetinib", 
            "intervention_type": "Drug", 
            "other_name": "AZD6244"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "HIV", 
            "Kaposi's sarcoma", 
            "Anti-retroviral therapy", 
            "AIDS"
        ], 
        "lastchanged_date": "December 14, 2012", 
        "link": {
            "description": "Health Protection Agency \"HIV in the United Kingdom\" Report 2009", 
            "url": "http://www.hpa.org.uk"
        }, 
        "location": [
            {
                "contact": {
                    "email": "Victoria.Sellick@bsuh.nhs.uk", 
                    "last_name": "Victoria Sellick", 
                    "phone": "01273 696955", 
                    "phone_ext": "3523"
                }, 
                "facility": {
                    "address": {
                        "city": "Brighton", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Brighton and Sussex University Hospitals"
                }, 
                "investigator": {
                    "last_name": "Sarah Westwell", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Amy Gladwell"
                }, 
                "facility": {
                    "address": {
                        "city": "Cambridge", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Addenbrookes Hospital"
                }, 
                "investigator": {
                    "last_name": "Kate Fife", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glasgow", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Beatson Institute"
                }, 
                "investigator": {
                    "last_name": "Diana Ritchie", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "amy.king@uhl-tr.nhs.uk", 
                    "last_name": "Amy King", 
                    "phone": "0116 258 6318"
                }, 
                "facility": {
                    "address": {
                        "city": "Leicester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Leicester Royal Infirmary"
                }, 
                "investigator": {
                    "last_name": "Stephen Nicolson", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "Alice.Shields@chelwest.nhs.uk", 
                    "last_name": "Alice Shields", 
                    "phone": "020 3315 6101"
                }, 
                "contact_backup": {
                    "email": "barbara.paracchini@chelwest.nhs.uk", 
                    "last_name": "Barbara Paracchini", 
                    "phone": "020 3315 2090", 
                    "phone_ext": "5036"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Chelsea & Westminster Hospital"
                }, 
                "investigator": {
                    "last_name": "Mark Bower", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "University College London"
                }, 
                "investigator": {
                    "last_name": "Siow-Ming Lee", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "smina.shahban@christie.nhs.uk", 
                    "last_name": "Smina Shahban", 
                    "phone": "0161 918 7355"
                }, 
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "The Christie Hospital"
                }, 
                "investigator": {
                    "last_name": "Michael Leahy", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Newcastle", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Royal Victoria Informary"
                }, 
                "investigator": {
                    "last_name": "Swethajit Biswas", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "c.crabtree@sheffield.ac.uk", 
                    "last_name": "Carol Crabtree", 
                    "phone": "01142 265 229"
                }, 
                "facility": {
                    "address": {
                        "city": "Sheffield", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Sheffield Teaching Hospitals NHS Foundation Trust"
                }, 
                "investigator": {
                    "last_name": "Penella Woll", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Southampton", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Southampton University Hospital"
                }, 
                "investigator": {
                    "last_name": "Peter Simmonds", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I/II Study of Oral MEK Inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination With Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposi's Sarcoma (KS).", 
        "overall_contact": {
            "email": "p.j.woll@sheffield.ac.uk", 
            "last_name": "Penella Woll", 
            "phone": "01142265235"
        }, 
        "overall_contact_backup": {
            "email": "l.r.crack@bham.ac.uk", 
            "last_name": "Laura Crack", 
            "phone": "01214147627"
        }, 
        "overall_official": [
            {
                "affiliation": "Chelsea & Westminster Hospital", 
                "last_name": "Mark Bower, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Beatson Institute, Glasgow", 
                "last_name": "Diana Ritchie, Dr.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Brighton and Sussex University Hospital", 
                "last_name": "Sarah Westwell, Dr.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Christie Hospital, Manchester", 
                "last_name": "Michael Leahy, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Royal Victoria Infirmary, Newcastle", 
                "last_name": "Swethajit Biswas, Dr", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Addenbrookes Hospital, Cambridge", 
                "last_name": "Kate Fife, Dr.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Leceister Royal Infirmary", 
                "last_name": "Stephen Nicolson, Dr.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "University College, London", 
                "last_name": "Siow-Ming Lee, Professor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Southampton University Hospital", 
                "last_name": "Peter Simmonds, Dr.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Objective Response Rates", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The primary outcome measure is to identify the safe recommended phase II dose using CTCAE version 4.0 criteria to assess dose limiting toxicity.", 
                "measure": "Toxicity of Selumetinib in combination with HAART.", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "reference": [
            {
                "PMID": "18390968", 
                "citation": "Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008 May 1;26(13):2139-46. Epub 2008 Apr 7."
            }, 
            {
                "PMID": "20179232", 
                "citation": "Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res. 2010 Mar 1;16(5):1613-23. doi: 10.1158/1078-0432.CCR-09-2483. Epub 2010 Feb 23."
            }, 
            {
                "PMID": "21594619", 
                "citation": "Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, Tebbutt NC. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs. 2012 Jun;30(3):1216-23. doi: 10.1007/s10637-011-9687-4. Epub 2011 May 19. Erratum in: Invest New Drugs. 2012 Jun;30(3):1272-3."
            }, 
            {
                "PMID": "18705759", 
                "citation": "Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo N, Powles T, Stebbing J, Wales N, Webb A; AIDS Malignancy Subcommittee. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med. 2008 Jul;9(6):336-88. doi: 10.1111/j.1468-1293.2008.00608.x."
            }, 
            {
                "PMID": "17227906", 
                "citation": "Cooley T, Henry D, Tonda M, Sun S, O'Connell M, Rackoff W. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Oncologist. 2007 Jan;12(1):114-23."
            }, 
            {
                "PMID": "17267331", 
                "citation": "Di Lorenzo G, Konstantinopoulos PA, Pantanowitz L, Di Trolio R, De Placido S, Dezube BJ. Management of AIDS-related Kaposi's sarcoma. Lancet Oncol. 2007 Feb;8(2):167-76. Review."
            }, 
            {
                "PMID": "2671281", 
                "citation": "Krown SE, Metroka C, Wernz JC. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol. 1989 Sep;7(9):1201-7."
            }, 
            {
                "PMID": "16051824", 
                "citation": "Sharma-Walia N, Krishnan HH, Naranatt PP, Zeng L, Smith MS, Chandran B. ERK1/2 and MEK1/2 induced by Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection. J Virol. 2005 Aug;79(16):10308-29."
            }, 
            {
                "PMID": "16679162", 
                "citation": "Stebbing J, Sanitt A, Nelson M, Powles T, Gazzard B, Bower M. A prognostic index for AIDS-associated Kaposi's sarcoma in the era of highly active antiretroviral therapy. Lancet. 2006 May 6;367(9521):1495-502. Review."
            }, 
            {
                "PMID": "12115328", 
                "citation": "Tulpule A, Groopman J, Saville MW, Harrington W Jr, Friedman-Kien A, Espina BM, Garces C, Mantelle L, Mettinger K, Scadden DT, Gill PS. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma. Cancer. 2002 Jul 1;95(1):147-54."
            }, 
            {
                "PMID": "17483315", 
                "citation": "Vart RJ, Nikitenko LL, Lagos D, Trotter MW, Cannon M, Bourboulia D, Gratrix F, Takeuchi Y, Boshoff C. Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6 and G-protein-coupled receptor regulate angiopoietin-2 expression in lymphatic endothelial cells. Cancer Res. 2007 May 1;67(9):4042-51."
            }, 
            {
                "PMID": "15220918", 
                "citation": "Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, M\u00e4kinen T, Elliman S, Flanagan AM, Alitalo K, Boshoff C. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat Genet. 2004 Jul;36(7):687-93. Epub 2004 Jun 27."
            }, 
            {
                "PMID": "17964626", 
                "citation": "Xie J, Ajibade AO, Ye F, Kuhne K, Gao SJ. Reactivation of Kaposi's sarcoma-associated herpesvirus from latency requires MEK/ERK, JNK and p38 multiple mitogen-activated protein kinase pathways. Virology. 2008 Feb 5;371(1):139-54. Epub 2007 Oct 26."
            }, 
            {
                "PMID": "10074203", 
                "citation": "Yang X, Gabuzda D. Regulation of human immunodeficiency virus type 1 infectivity by the ERK mitogen-activated protein kinase signaling pathway. J Virol. 1999 Apr;73(4):3460-6."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01752569"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Analysis of PBMC in a sub-study", 
                "measure": "PBMC sub-study", 
                "safety_issue": "No", 
                "time_frame": "2.5 years"
            }, 
            {
                "description": "The number of cycles of Selumetinib treatment in combination with HAART.", 
                "measure": "Number of completed cycles", 
                "safety_issue": "No", 
                "time_frame": "2.5.years"
            }, 
            {
                "measure": "HIV viral load and CD4 count", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Phase I only", 
                "measure": "HAART Drug levels", 
                "safety_issue": "No", 
                "time_frame": "1 years"
            }, 
            {
                "description": "Phase I only", 
                "measure": "Selumetinib and metabolite serum levels", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Pharmacodynamic measures of Selumetinib in combination with HAART - serum angiogenic biomarker levels and pERK in tumour tissue.", 
                "measure": "Serum angiogenic biomarkers levels", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "source": "Sheffield Teaching Hospitals NHS Foundation Trust", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Cancer Research UK Clinical Trials Unit, Birmingham UK", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "AstraZeneca", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Fisher Clinical Services Ltd. (drug supply)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Cancer Research UK (funding)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of Sheffield", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Sheffield Teaching Hospitals NHS Foundation Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}